World Library  
Flag as Inappropriate
Email this Article

Methyl aminolevulinate

Article Id: WHEBN0006608023
Reproduction Date:

Title: Methyl aminolevulinate  
Author: World Heritage Encyclopedia
Language: English
Subject: MAL, Protoporphyrin IX, Basal-cell carcinoma, Chemotherapy, Cell-cycle nonspecific antineoplastic agents
Collection: Antineoplastic Drugs, Methyl Esters, Prodrugs
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Methyl aminolevulinate

Methyl aminolevulinate
Systematic (IUPAC) name
methyl 5-amino-4-oxo-pentanoate
Clinical data
AHFS/Drugs.com
Identifiers
CAS Registry Number  Y
ATC code L01
PubChem CID:
DrugBank  Y
ChemSpider  Y
ChEMBL  N
Chemical data
Formula C6H11NO3
Molecular mass 145.156 g/mol
 N   

Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix.

Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.

Metvix is developed by Photocure and Galderma has bought all rights to Metvix.[1]

Approvals and indications

Interim result of phototherapy for actinic keratosis with Metvix one week after exposure. Patient has light skin and blue eyes.

Methyl aminolevulinate is approved in New Zealand for treatment of basal cell carcinoma.[2]

It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).[3]

It has some advantages over Levulan.[4]

It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. [5]

References

  1. ^ http://photocure.com/NEWS/newcontainer/Photocure-divests-Metvix-to-Galderma-for-EUR-51-million/ Photocure divests Metvix to Galderma
  2. ^ http://dermnetnz.org/procedures/metvix-pdt.html "Methyl aminolevulinate photodynamic therapy (MAL PDT)"
  3. ^ http://www.medicalnewstoday.com/articles/eng/36953.php "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment" 2006
  4. ^ http://findarticles.com/p/articles/eng/mi_qa3931/is_200909/ai_n42040200/pg_13/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009 by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
  5. ^ http://www.abc.net.au/news/2013-11-16/concerns-raised-over-side-effects-of-skin-cancer-cream/5096496


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.